Three patients’ tumors showed mutations in TSC1, while one had a mutation in PTEN, and some of these patients had been included in our previous study showing that there is enrichment for mutations in mTOR pathway genes in RCC patients who respond to rapalog therapy [14]. This evidence concerns the gene PTEN and renal cell carcinoma.